San Francisco, CA, United States of America

Jeffrey A Bluestone

This inventor holds 17 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Immunotherapy Research. Top assignees: University of California, Pfizer Corporation, Leland Stanford Junior University. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey A Bluestone. Retrieved from https://idiyas.com/inventor/jeffrey-a-bluestone

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 16)

% Patents Active = 94.1

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 9)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 96(Granted Patents)

Company Filing History:

15 out of 16,071

University of California

Leland Stanford Junior University

The United States Government as Represented by the Department of Veterans Affairs

patents

6. 1 out of 1

U.S. Government Represented by the Department of Veteans Affairs

patent

7. 1 out of 834,681

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Anti-IL-2 Antibodies

Regulatory T Cells

Pancreatic Islet Grafts

Glycosphingolipids

CD127 Expression

CAR-T Cells

NKG2D Modulation

Immune Disorders

LFA3 Variant Polypeptides

Autoimmunity

Immunosuppressive Activity

Hematopoietic Graft

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595301 - ANTI-IL-2 ANTIBODIES AND COMPOSITIONS AND USES THEREOF (2026-04-07),

2. 12502410 - Preservation of pancreatic islet grafts in the extrahepatic space (2025-12-23),

3. 12436150 - CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs (2025-10-07),

4. 12421302 - CAR-t cells and autoimmune diseases (2025-09-23),

5. 12103958 - Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions (2024-10-01),

6. 11951136 - Preservation of pancreatic islet grafts in the extrahepatic space (2024-04-09),

7. 11459385 - Anti-IL-2 antibodies and compositions and uses thereof (2022-10-04),

8. 11435349 - [object Object] (2022-09-06),

9. 10738113 - Anti-IL-2 antibodies and compositions and uses thereof (2020-08-11),

10. 10227290 - Glycosphingolipids for use in modulating immune responses (2019-03-12),

11. 10138298 - Anti-IL-2 antibodies and compositions and uses thereof (2018-11-27),

12. 9977021 - CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ tregs (2018-05-22),

13. 9801911 - Expansion of alloantigen-reactive regulatory T cells (2017-10-31),

14. 9211328 - Modulation of NKG2D for prolonging survival of a hematopoietic graft (2015-12-15),

15. 9012134 - [object Object] (2015-04-21),

Title: The Innovative Journey of Jeffrey A. Bluestone

Introduction: Jeffrey A. Bluestone is a renowned inventor based in San Francisco, CA (US) known for his groundbreaking contributions to the field of biotechnology and healthcare.

Latest Patents: Jeffrey A. Bluestone holds several patents related to novel immunotherapies and treatments for autoimmune diseases, showcasing his commitment to advancing medical science through innovation.

Career Highlights: With a distinguished career spanning several decades, Jeffrey A. Bluestone has held key positions in leading research institutions and biotechnology companies, where he has spearheaded numerous projects that have revolutionized the healthcare industry.

Collaborations: Throughout his career, Jeffrey A. Bluestone has collaborated with top researchers, scientists, and healthcare professionals, fostering a culture of innovation and knowledge sharing in the field of biotechnology.

Conclusion: Jeffrey A. Bluestone's relentless pursuit of innovation and his passion for improving healthcare have solidified his reputation as a pioneering inventor in the biotechnology sector.

Profile summary based on public USPTO records.